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Translating the knowledge from biomedical science into clinical applications that help patients has been compared
to crossing a valley of death because of the many issues that separate the bench from the bedside and threaten to
stall progress. But translation is also inhibited by a science policy environment with its own impediments. Mapping
these policy impediments give a more complete picture of the valley of death. Stem cell science is one example
where success in moving from the bench to the bedside has confronted policy challenges generating difficulties as
challenging as those facing scientists and clinicians. We highlight some of the characteristics and challenges of the
science policy valley of death common to the U.S. and Europe, illustrate them with a recent example from stem cell
science, and describe some promising strategies for traversing the valley.
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In biomedicine a translational paradigm has been re-
cently adopted to accelerate the pace of scientific pro-
gress [1] by focusing attention on the bottlenecks that
constitute the so-called “valley of death”, a place in
which promising basic research findings go that fail to
make their way into (or out of) clinical trials and there-
fore never have a chance to develop into therapies for
patients. But progress in translational medicine is also
shaped by science policy, a broad term referring to all ef-
forts to apply science for the benefit of society whether
by the public or private sector [2]. We believe that sci-
ence policy faces its own valley of death, but that com-
paratively little attention has been given to understanding
it in the era of globalized, translational science. We here
address the analogy between translational research and
science policy development: the detrimental effect of inad-
equate science policy on translational science and: possible
ways of improving the science policy process.
Various images are used to portray the bench-to-bedside
valley: among the first was of a narrow chasm separating
two rocky cliffs. But as translational science evolved so too* Correspondence: emeslin@iu.edu
1Indiana University Center for Bioethics, 410 West 10th Street, 46202
Indianapolis, USA
2UMR 1027, Inserm, Université Toulouse III - Paul Sabatier, 31000 Toulouse,
France
© 2013 Meslin et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is phas the image of this valley topography: rather than one
valley, two distinct valleys emerged, the first separating
basic research from clinical science, and a second separat-
ing clinical science from clinical practice and health deci-
sion making [3]. The two valleys have now morphed into
five phases of translational research separating four val-
leys: basic discovery science to research involving humans
(T1), from human studies to evidence-based guidelines
(T2), from guidelines to health practice (T3), and from
health practices to population health programs (T4) [4].
These alternative versions of the valley of death metaphor
are summarized in Figures 1 and 2.
The valley metaphor helps explain the impediments
that prevent biomedical science from realizing its poten-
tial and the risks of failing to translate knowledge into
public benefit. The impediments range from lack of
technological innovation or “old style thinking” [1], to
particular obstacles such as a lack of access to well char-
acterized biological materials in biobanks [5], or insuffi-
cient training in translational science for the next
generation of investigators [6]. The principal risks of fail-
ing to translate this science are the perceived delays in
providing diagnostics and clinical care to patients [7,8].
Overcoming these challenges was a key justification for
developing translational platforms such as the National
Institutes of Health (NIH) Clinical Translational Science
Awards (CTSA) program, the Food and Drug Adminis-n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Three hills and two translational valleys from basic research to clinical practice.
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vanced Translational Research InfraStructure (EATRIS)
in Medicine program, public-private partnership pro-
grams like the Innovative Medicines Initiative in Europe,
and similar private sector initiatives. All emphasize
closer collaboration between investigators, institutions,
communities, and sponsors throughout the research
lifecycle. Progress in this domain has been slow but
steady. Benchmark criteria for achieving success in
translational science have been developed [9] and re-
ports of success are being made [10,11]. But sustainedFigure 2 Five hills and four translational valleys from discovery to poprogress in biomedical science may depend as much on
successfully navigating the dangers of the policy valley as
on successfully accelerating translational science itself.
On one side of the policy valley we may find broad nor-
mative visions about how society might benefit from sci-
ence progress, innovation and technology development;
on the way across the valley lies many varied and prag-
matic instantiations of those diverse visions including
appropriation decisions, legislation, regulations, guid-
ance documents and other policy instruments for the
governance of science and medicine along a translationalpulation health.
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instruments and how they map onto the many valleys
illustrated in Figure 2.
Getting from one side to the other involves navigating
through a diverse collection of organizations and institu-
tional players – government, private sector and lobbyists
among them. Particular challenges include ambiguous
regulation [12], unnecessary bureaucracy [13], lack of
commercial incentives to innovate [14], and few oppor-
tunities to revise legislation or to change habits or prac-
tices in the light of new knowledge. Collectively these
items stifle the formation of a favorable regulatory envir-
onment for innovation, just as readily as does the lack of
access to biospecimens, informatics expertise, or nimble
ethics review.
Science policy implies differences in focus, needs and
strategy [15] which, if not addressed, may severely ham-
per the efficiency of the translational process. Consider
funding as an example. In an 1864 letter to the French
Ministry of Public Instruction, Louis Pasteur requested
additional funding for his fermentation research by
underlining its importance for the French wine business
[16]. This historical example reminds us that science
funding is one of the most visible (and vigorous) chal-
lenges in science policy. Indeed, by most accounts the
billions of dollars spent to increase the NIH budget and
for similar commitments to “frontier research” by the
European Union have been well spent from the perspec-
tive of both the basic and applied sciences. But if
deployed poorly, science policy can do the opposite: it
can stifle the creative pursuit of knowledge, bar access to
treatments by inhibiting the approval process for medi-
cines [17] or discourage scientists from pursuing promi-Figure 3 Policy instruments in the translational policy continuum.sing avenues of inquiry [18]. One may look no further
than the fiscal cliff off of which U.S. science funding has
plummeted, or the comparable reductions in Europe’s
proposed Horizon 2020 budget to find examples of how
science policy funding decisions create risks for science.
The impact of a $2.5 Billion cut from the US science
budget is now trickling down to every public university.
In Europe the impact on young investigators would
be especially dire and will have a profound impact
on society [19].
While fiscal cliffs and funding decisions rightly occupy
political attention, and are often held hostage to political
ideology, some science policy involves legitimately con-
troversial ethical topics for which a policy pathway
across the valley would be welcomed. Below we consider
the case of stem cell research, especially embryonic stem
cell research, as an example whose history demonstrates
how success in crossing the biomedical science valley
may be hampered by an inadequate policy map. Other
examples could also illustrate the process, such as gene
patenting, use of existing biological samples for research,
data sharing according to funding used for research.
Embryonic stem cell science and stem cell policy
Embryonic stem cell science may optimistically be char-
acterized as moving across the T1 valley from basic dis-
coveries to initial applications in health – though even
recent developments, such as the report of the first
cloned human stem cells [20], remind us that basic sci-
ence work continues in this field. There was a time not
long ago, however, when it might not have been pursued
at all. Beginning with the momentous announcement in
early November 1998 that human embryonic stem cells
Meslin et al. Clinical and Translational Medicine 2013, 2:14 Page 4 of 8
http://www.clintransmed.com/content/2/1/14had been isolated [21] strategies for translation were
hindered by numerous ethical and political hurdles. Even
early claims of success turned out to be either unsup-
ported [22] or patently false [23]. Science persisted with
successes reported in other areas of stem cell science,
among them Yamanaka’s Nobel prize-winning work on
induced pluripotent stem cells [24]. Arguably, however,
these advancements may have occurred despite the pol-
icy environment rather than because of it. For example,
in the immediate aftermath of the 1998 reports U.S.
President Clinton requested that the National Bioethics
Advisory Commission advise on next steps [25] which
was followed by actions from the NIH, FDA, the Insti-
tute of Medicine, Congress and two presidents to craft
U.S. domestic federal policy that is still somewhat unset-
tled. This was despite more than two decades of policy
deliberation in the US about ethics of embryo research.
Many other jurisdictions including those in Europe de-
veloped evolving policy in parallel with the U.S. For ex-
ample, France’s first bioethics law in 1994 prohibited
research on embryo stem cells and evolved over time:
following revisions of the law in 2004 certain exceptions
to the prohibition were permitted, then a revision of
these conditions were described in 2011, and most
recently in 2013 ES cell research was proposed to be
authorized with conditions. Others established country-
specific rules ranging from permissive, albeit highly regu-
lated regimes, to restrictive laws forbidding the isolation of
stem cells from human embryos under any circumstances
[26]. The policy landscape at that time included no short-
age of recommendations, regulations, guidelines and legis-
lation but rather than offering a clear path for translational
medicine they were often unclear, ambiguous and some-
times contradictory. In some instances the uncertainty was
shown to have demonstrable (and substantially detrimen-
tal) effects on the conduct of stem cell science as reported
by scientists themselves [18]. This ‘patchwork’ approach
was found in other countries leading to frustration and
confusion by scientists and sponsors [27].
While some efforts to reduce uncertainty have been
achieved [28], progress across the policy valley still faces
impediments as two recent examples illustrate. In
August 2012, the US district court for the District of
Columbia issued a landmark decision (USA v. Regenera-
tive Sciences) confirming that the FDA has jurisdiction
over the commercialization of autologous mesenchymal
stem cell therapies [29]. Later the same month, an
Italian judge took the opposite position authorizing
heterologous injections of mesenchymal stem cells in a
two year-old girl affected by spinal muscular atrophy, a
condition that is currently incurable [30]. The procedure
was conceived and already undertaken on a number of
patients by a physician collaborating with a not-for
-profit organization called Stamina Foundation. Theirmethod, however, was not supported by any published
pre-clinical or clinical data about the safety and efficacy
of the procedure. For this reason, AIFA – the public
agency that oversees medical drugs in Italy – had ini-
tially prohibited Stamina from carrying out the proced-
ure on patients. Once the Italian judge’s decision
established a precedent, identical ones followed suit as a
growing number of families sought to continue or access
the same procedure for their children.
What is particularly troubling is that the alleged treat-
ment was administered under a so-called compassionate
use protocol, which is tightly regulated by Italian legisla-
tion. It seems, however, that this did not prevent the
judges from interpreting the law in a way that overlooked
two crucial legal requirements for compassionate use of
unproven cellular therapy: first, the existence of published
scientific evidence justifying the procedure and, second,
a favorable risk-benefit assessment by a local ethics
committee.
The case did not escape the attention of the scientific
community that roundly condemned the Stamina pro-
cedure and the permissive attitude of the Italian judges
[31,32]. In a statement from the International Society for
Stem Cell Research (ISSCR), Yamanaka bemoaned the
Italian decision, stating that “stem cell therapy and treat-
ment decisions should not be made outside of a controlled
clinical trial with data on safety and efficacy” [33].
Notwithstanding their obvious shortcomings a mount-
ing wave of public support for an alleged right to access
those unproven infusions, pushed the Ministry of Health
to issue an ad hoc executive decree. The latter was re-
cently amended and approved by the Italian Parliament
and it is based on two controversial elements: first, for
the next eighteen months the Stamina method, albeit
unproven, will be freely available to patients affected by
rare diseases; second, the State will allocate three million
Euros to sponsor a clinical trial designed to test the
safety and efficacy of the Stamina procedure.
The Italian judicial decision and the Parliamentary de-
bate that brought to the ratification of the ministerial de-
cree are clear examples of the messiness of the policy
process and the dangerous consequences of inadequate
policy support. But the Italian policy steps are also illus-
trative of an important shift of emphasis: the moral
status of the embryo which for years dominated the de-
bates about the permissibility of embryonic stem cell re-
search is no longer the main impediment to the progress
of stem cell science. Rather, policy may now be the prin-
cipal impediment to its sustained progress, especially
when it may be used to support dubious hopes and per-
mit use of public resources for purposes that lack evi-
dence. There is a lesson here: as science moves into
controversial areas, public expectations will have to play
a role in shaping the direction of research and
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reasonable demands on the part of the public with re-
spect to scientific innovation. As the Italian case seems
to demonstrate, a better understanding is required of the
right balance between scientific promises and attainable
futures, and of the proper relationship between expert
communities, decision makers and the diverse publics
affected by science policy decisions.
Crossing the policy valley
Several promising areas are emerging that indicate ways
the policy valley can be more effectively crossed. Here
we highlight four of them.
Renegotiate the science social contract with society
For more than six decades many countries sought to im-
plement their own version of Vannevar Bush’s “endless
frontier” in which science would not only provide solu-
tions to health problems but enhance wealth and pros-
perity [34]. The structuring of universities to engage in
teaching and research, the establishment of major bio-
medical research organizations, and the dramatic in-
creases in public funding for science were hallmarks of
the second half of the 20th century’s “frontier”. In many
countries in Europe as well as in USA these were the
policy acts of an implied social contract the terms of
which were straightforward: in exchange for public
support, the scientific community would be granted sub-
stantial autonomy to conduct research with the expect-
ation that the products of their investigations would be
returned to society in the form of knowledge and applied
technology [35]. Generally speaking, like the social con-
tract theory developed by Hobbes, Locke, Hume, and
Rousseau, which described the optimal relationships be-
tween individuals and government, society’s contract
with science was also intended to function for the recip-
rocal benefit of both. This has been particularly so for
“big science” projects which promote social cohesion or
other political goals such as Europe’s decision to build
CERN, President Kennedy’s push for the moon, or the
Human Genome Project. It has also been a common jus-
tification for translational research generally [36].
While the metaphorical social contract may have func-
tioned for several decades, in recent years calls to radic-
ally update or retire it completely have grown [37]. Even
if we undertake a thorough re-thinking of the way soci-
ety ought to interact with science [38] it is unlikely that
a renewed social contract alone will be sufficient to deal
with the policy challenges arising in stem cell science or
other controversial topics. Not only does the format of
science-society interactions need re-adjustment but so
too does the very positioning of these activities in the re-
search and policy decision processes. A recent European
Science Foundation (ESF) report indicates that the clas-sical social contract for science is no longer operational
and proposes several recommendations, two of which
we would like to underline as they are of immediate
relevance to the issues addressed here [39]. First, the
ESF calls for “expanding and creating new spaces for
science-society interactions” insisting on bottom-up ini-
tiatives and creativity in this domain. The expected ad-
vantage of effective public engagement in shaping the
direction of innovative science is the broadening of the
innovation agenda to a wider array of values and in-
terests. Second, the ESF report advocates enhancing the
opportunities for reflexive assessment of scientific in-
novation. Reflexive thinking refers to the capacity to put
under critical scrutiny the assumptions, expectations,
values and visions of the future that are embedded
in specific modalities of producing knowledge and
innovation. Those visions shape the pace and direction
of science, and drive the ‘competition race’ that charac-
terizes today’s science. However, they are rarely made
the object of sustained analytical attention. Instead, we
believe that occasions for reflexive assessment of science
with respect to broader sets of societal values should be
abundant. This means incentivizing research in the hu-
manities and the social sciences about how innovation
relies on societal expectations and, at the same time,
how societal expectations are determined by scientific
novelties. The governance of science has such a per-
vasive societal impact that it deserves state-of-the-art
analytic tools for its assessment and improvement. Fur-
thermore, reflexivity also implies that even the proposed
modalities of engagement between science and society
are constantly questioned, assessed and, where possible,
improved. Research in this domain is thus crucial and
this brings us to our next indication.
Gathering the evidence base for science policy
If we are to be serious about harnessing the potential of
science in the interest of society, we need governance
initiatives that, rather than prompting ideological con-
frontation, are able to occasion upstream, reciprocal
learning between science and society and thus intelli-
gent, evidence-based decision making about scientific re-
search and its various applications [38,39]. One such
initiative with which two of us are associated is called
‘ELSI 2.0’, an innovative international collaboratory that
is designed to engage more international collaboration
in the ethical, legal and social implications of genomics
research and accelerate translation from research to
practice [40]. ELSI 2.0 will function by leveraging the co-
operative power of many individuals, groups and stake-
holders across the globe through shared research
platforms, mixed-methods for engagement, and other
approaches to accelerate the efficient and effective appli-
cation of genomics for society. Other promising deve-
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that emerged from 48 science policy experts who
recommended 40 key questions to “catalyse and focus
research in this field” [41], the ongoing efforts to collect
data about policy influences [42], and the recent
establishement of a database on global health research in
Africa developed by many of the world’s foremost
funding bodies [43]. These efforts are necessary steps to
empirically understand the impediments to implemen-
ting science policy and to combine these with needed
ethical reflection. We encourage more efforts to gather
empirical data about the possible impact of different
governance options of novel science and technology.
While we are confident that a more inclusive public dia-
logue about science and well-designed participatory ini-
tiatives are per se promising tools for improving the
governance of scientific innovation, it is indispensable
that such discussions rely on a solid evidence base to
reach beyond academic circles, and to be taken into con-
sideration at the policy level.
Reframing funding priorities
The public investment in science is too often justified
mainly for its capacity to generate jobs and to attain pri-
macy in the geopolitical competition of the global know-
ledge economy [44-46]. Whereas in the short-term this
narrative can provide a good deal of resources for sci-
ence, in a medium to long-term perspective it can stifle
its development and curtail its expectations, should
other sectors come to be seen as more appealing for
public investment. Science funding, in other words,
should be inspired by the value of science itself including
its interactions with society and capacity of reflexivity as
a very part of scientific activity. Emphasis on derivative
aims such as economic development, while important,
may risk avoiding the need to critically assess the soci-
etal mission of science. Science has so much to offer that
it should not be afraid of engaging is such reflexive exer-
cise: quite to the contrary, open dialogue in this domain
can revitalize and update its role in society.
Acknowledge common goals
Science policy rarely proceeds in an orderly fashion. This
is because policy construction, development, revision,
public input, implementation and evaluation form a
complex system undertaken over long periods of time,
by multiple actors located in multiple sites who are
influenced by contextual, economic and other political
factors. Science policy is complex for another reason, in
that it is often responsive to unplanned events. Despite
these factors there are some hopeful signs for deploying
science policy more effectively. Japan’s recent experience
in response to its devastating tsunami showed that pub-
lic trust is a necessary activity for countries seeking toimplement science policy-making [47]. This view is con-
sistent with calls to democratize science which will re-
quire sustained critical reflection and creative political
experimentation [48] in setting up inclusive governance
initiative for innovation across a variety of scientific do-
mains. Democratization, however, faces two major chal-
lenges. On the one hand, more inclusive governance
processes may end up including non-reconcilable visions
and values. The Stamina case, for example, raises a num-
ber of doubts about how we may be able to reduce the
gap between radically diverging framings of regenerative
medicine. The second challenge arises from the global
environment in which scientific innovation is occurring
especially regarding coordinated governance initiatives
across a complex environment of cultural, political and
social variation.
However, both challenges represent a stimulus for a
more sustained interaction between science, the social
sciences and the humanities to construct the founda-
tions for tomorrow’s initiatives in international science
policy. Returning to the example of embryonic stem cell
research, these are still early days of stem cell policy
innovation – so it is hard to craft science policy accept-
able to society for supporting research and development
in the service of the public good when it is difficult to
predict where the science and its applications are likely
to go. And yet that is precisely the role of science policy.
Much effort was expended in the early days of embry-
onic stem cell research to design appropriate guidelines
for laboratory-based activities. These problems have now
been replaced by others such the issue of unproven stem
cell therapies and stem cell tourism which, arguably, are
in greater need of a coordinated approach to global sci-
ence policy. Both topics can exploit regulatory loopholes
and country-specific differences, yet so far, the only kind
of international governance action has been taken by
self-regulating scientific societies such as the ISSCR
[28,49]. In the absence of trusted national authorities to
adjudicate on matters of science, or global institutional
bodies with enough credibility to speak to these issues,
renewed attention should be paid to global governance
in stem cell research, as we are now beginning to see for
areas such as research involving biobanks [50].
Summary
Science policy lies at the intersection of science and
public policy. Its objects are the proper funding of and
priority-setting for the governance of science, the regula-
tion and conduct of research, and all related efforts to
apply science for the benefit of society. Science is also a
global, interconnected activity and as such the develop-
ment of science policy in one country implicates citi-
zens, scientists and governments in other countries. As
stem cell science illustrates, this landscape is changing
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tific innovation is fraught with possible controversies,
spanning from ethical to societal and legal ones. There-
fore, a long-term public commitment in favor of science
cannot be decoupled from the necessity to exert reason-
able forms of oversight on scientific research and its ap-
plication. Managing public disagreement about science
in a way that can be perceived as legitimate across the
broadest possible range of moral perspectives [51] is cer-
tainly no easy task. This task should thus inspire more
sustained and dedicated efforts at analyzing the impact
of science policy options on the course of scientific
innovation: we need to engage in reflexive and imagina-
tive thinking about science and science policy implica-
tions. Only by giving the same attention to bridging
science policy’s valley of death as we do to biomedical
research translational process, prospects can be favor-
able for the effective translation of science into collect-
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